Long-term implant fibrosis prevention in rodents and non-human primates using crystallized drug formulations

利用结晶药物制剂预防啮齿动物和非人灵长类动物的长期植入物纤维化

阅读:2
作者:Shady Farah # ,Joshua C Doloff # ,Peter Müller ,Atieh Sadraei ,Hye Jung Han ,Katy Olafson ,Keval Vyas ,Hok Hei Tam ,Jennifer Hollister-Lock ,Piotr S Kowalski ,Marissa Griffin ,Ashley Meng ,Malia McAvoy ,Adam C Graham ,James McGarrigle ,Jose Oberholzer ,Gordon C Weir ,Dale L Greiner ,Robert Langer ,Daniel G Anderson

Abstract

Implantable medical devices have revolutionized modern medicine. However, immune-mediated foreign body response (FBR) to the materials of these devices can limit their function or even induce failure. Here we describe long-term controlled-release formulations for local anti-inflammatory release through the development of compact, solvent-free crystals. The compact lattice structure of these crystals allows for very slow, surface dissolution and high drug density. These formulations suppress FBR in both rodents and non-human primates for at least 1.3 years and 6 months, respectively. Formulations inhibited fibrosis across multiple implant sites-subcutaneous, intraperitoneal and intramuscular. In particular, incorporation of GW2580, a colony stimulating factor 1 receptor inhibitor, into a range of devices, including human islet microencapsulation systems, electrode-based continuous glucose-sensing monitors and muscle-stimulating devices, inhibits fibrosis, thereby allowing for extended function. We believe that local, long-term controlled release with the crystal formulations described here enhances and extends function in a range of medical devices and provides a generalized solution to the local immune response to implanted biomaterials.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。